

Mechanistic Modeling of Viral Particle Production

Christopher T. Canova^{‡1}, Pavan K. Inguva^{‡1}, and Richard D. Braatz^{*1}

¹Department of Chemical Engineering, Massachusetts Institute of Technology, 77
Massachusetts Avenue, Cambridge, MA 02139, USA

Data Availability Section

No data are available for this work.

[‡]Authors contributed equally to this work

^{*}Corresponding author. Email: braatz@mit.edu

Abstract

Viral systems such as wild-type viruses, viral vectors, and virus-like particles are essential components of modern biotechnology and medicine. Despite their importance, the commercial-scale production of viral systems remains highly inefficient for multiple reasons. Computational strategies are a promising avenue for improving process development, optimization, and control, but require a mathematical description of the system. This article reviews mechanistic modeling strategies for the production of viral particles, both at the cellular and bioreactor scales. In many cases, techniques and models from adjacent fields such as epidemiology and wild-type viral infection kinetics can be adapted to construct a suitable process model. These process models can then be employed for various purposes such as in-silico testing of novel process operating strategies and/or advanced process control.

Keywords— Mathematical modeling, Dynamics, Upstream biomanufacturing, Viruses, Virus-like particles

1 Introduction

Viral systems such as wild-type viruses, viral vectors (e.g., Adeno-Associated Viruses (AAVs) and retroviruses [1]) and virus-like particles (VLPs) have become essential components of modern biotechnology and medicine. These systems are used in the production of vaccines (e.g., inactivated or attenuated whole viral vaccines [2], viral vector vaccines [3], and VLP-based vaccines [4]), vaccine adjuvants and antiviral therapies [5], gene therapies [1], recombinant protein production [6, 7], and drug delivery [8, 9].

The successful development and commercialization of many of these biotherapeutics require large-scale and high-yield production of these viral systems. Scaling up and optimization of viral system manufacturing processes are currently active areas of research. Some of the challenges are generally applicable to most viral systems, e.g., inefficient downstream separation and purification [10], while others are system specific, e.g., low yields in recombinant AAV (rAAV) production due to inefficient filling of capsids with the desired genetic material [11]. These challenges have motivated significant research activity throughout the manufacturing and development pipeline e.g., engineering and optimizing cell lines [12, 13], engineering the viral system itself to facilitate production [14, 15], bioreactor process development and intensification [12, 16], and improving the performance of downstream separation processes [10, 17].

One of the comparatively nascent developments in the viral systems production literature, which motivates this review, is the development and application of mathematical modeling approaches to understanding the manufacturing process both at the cellular and reactor scales. The use of modeling strategies in biotechnology is well-established (a cursory search of the literature will reveal a plethora of studies and reviews on the topic e.g., [18, 19]) and has significantly contributed to the development of the field. Incorporating modeling into the process research and development workflow can contribute several benefits such as providing deeper process insights into the dynamics and multivariable interactions present in the system [11, 20], enabling the deployment of advanced process control and monitoring strategies [20, 21], enhance process optimization methodologies [22], and guide and accelerate the development of novel manufacturing strategies [11, 23].

Fortunately, the development of process models for viral systems manufacturing is significantly aided by a comprehensive preexisting literature in adjacent fields such as wild-type viral infection, epidemiology, and chemical/biochemical reactor engineering. At the cellular scale, detailed studies on the viral life cycle and infection kinetics provide the basis for mapping the intracellular process steps and can serve as initial kinetic estimators. At the reactor scale, the interactions between viruses and cells can be coarse-grained and approximated by functional forms that are analogous to the compartment-modeling frameworks used to study infection at the scale of an individual human or a population. These human-scale (e.g., [24–26]) and population-scale models (e.g., [27, 28]) are commonly used tools to understand disease progression and the impact of specific interventions like anti-viral therapies or vaccination programs. Multiscale approaches that combine cellular- and reactor-scale modeling are also commonly employed in the literature for similar applications.

This review aims to consolidate existing literature on the dynamical modeling of upstream viral systems manufacturing and outline a robust approach for constructing novel models. By breaking down the required model constituents and processes at both the cellular and reactor scales, we show how a model can be formulated using information and strategies from the various aforementioned fields.

2 Cellular-scale Models

2.1 Model Constituents

Cellular-scale models of viral processes describe the steps that map the viral production processes within an individual cell. The specific steps vary, but in general capture uptake, unpacking, transport, replication, transcription, translation, budding, and release processes occurring within the cell. Figure 1 provides an overview of the steps often included in cellular-scale reaction-transport models of viral systems.

When establishing a cellular-scale model, the delineation of the model steps depends broadly on four characteristics:

1. **Virus Type:** The type of wild-type virus, viral vector, or VLP.
2. **Cell Type:** The type of cells being used to generate the virus, e.g., mammalian cells such as HEK293 or insect cells such as Sf9. The cell type also impacts the kinetic parameter values used in the model.
3. **Genetic Expression Approach:** The method of expressing the gene(s) of interest, e.g., transient transfection, stable expression, or wild-type infection.
4. **Data Availability:** The utility of the model depends on the type and quality of the available experimental data.

Unlike wild-type infection models, which seek to understand the timing and dynamics of wild-type viral infection, recombinant models depict the cellular production of viral vectors or VLPs for therapeutic or experimental use. Although recombinant viral system modeling is a less mature area of development, models have been created for viral vectors [11, 29], attenuated viruses for vaccines [30], and VLPs [31, 32]. Figure 2 shows an exemplar cellular-scale model output, in which the dynamics of a transient AAV system are predicted and mapped to experimental measurements [11]. For a thorough overview of wild-type infection models, refer to Ref. [33].

The focus of this section of the review is the mathematical approaches that enable cellular-scale viral modeling. These mathematical strategies are often application agnostic, and can be readily applied to either wild-type or recombinant systems.

2.2 Mathematical Approaches

Cellular-scale models can be broadly categorized as either deterministic or stochastic. Deterministic models neglect the inherent randomness and noise of the biological system and provide precise predictions. While the insights gleaned from deterministic models are often useful, biological systems are inherently random, and stochastic elements can be included to describe variations observed in experiments and to capture a more complete understanding of the system dynamics [34, 35]. Srivastava *et al.* [36] is a helpful primer on the differences of applying deterministic and stochastic modeling approaches to viral systems.

2.2.1 Deterministic Modeling

Deterministic models of viral systems often employ a system of ordinary differential equations (ODEs) or differential-algebraic equations (DAEs) to describe the cellular-scale mass action kinetics. This approach assumes species homogeneity within the cell. The steps outlined in Fig. 1 provide an overview of the steps often included in ODE- or DAE-based reaction-transport models of recombinant viral systems. Three methods of gene delivery and production are highlighted: (a) gene delivery through plasmid transfection, (b) gene delivery through recombinant viral infection and receptor mediated endocytosis and (c) a stable producing cell line. Note that not all steps are relevant to all viral systems.

There is no consensus on the mathematical approaches used to describe many of the cellular-scale steps depicted in Figure 1. Some mathematical approaches are summarized in Tables 1-2. Many of the differences in approach are driven by differences in virus or application, but differences are also caused by a lack of understanding of the precise mechanisms occurring at the process step, which is often rooted in experimental limitations that make it difficult to extract the granular kinetic details of the complex biological interactions occurring in each step. Because of this, the steps included in cellular-scale models often describe lumped phenomena.

As an example, consider the assembly step. Viral assembly is a complex process with many sub-steps: the capsid proteins assemble, the nucleic acid becomes encapsulated within the capsid, and, in some cases, the virus obtains a membrane coat. Modeling these interactions is an active area of research, and detailed mechanistic and physics-based models exist that can provide a thorough description for many viral and VLP systems [37, 38]. However, as shown in Table 1, the assembly rate of the viral particles and VLPs is often approximated in cellular-scale dynamical models using Michaelis-Menton kinetics [39–41], limiting-substrate kinetics [11, 42, 43], or thermodynamic [31] approaches. When building an integrated cellular-scale model, a balance between detail and computability needs to be struck. If the approximation accurately predicts the rate and stoichiometry of the step, the model conclusions should be sufficient for making population-scale productivity and product quality assessments.

Even when a step’s high-level mathematical structure is the same, the equation details can differ. For example, multiple groups have modeled the transcriptional regulation of gene expression by tracking the number of ribosomes available for translating the mRNA into protein [40, 42, 44, 45]. The models of Binder *et al.* [45] and Zitzmann *et al.* [40] include ODEs for the translation complexes that form when an mRNA binds to a ribosome. Each translation complex represents a polyribosome, and a cap is placed on the number of ribosomes available inside the cell. Aunins *et al.* [42] also uses ODEs to describe the formation of translation complexes, but include an additional ODE that tracks the number of available ribosomes. Lim *et al.* [44] instead uses an algebraic approach in which ribosomes are assigned to the various mRNAs based on their length.

2.2.2 Stochastic Modeling

The propagation of stochastic effects often leads to cell-to-cell heterogeneity in viral systems. Including stochastic elements in cellular-scale models can capture this heterogeneity, providing a more robust assessment of the range of possible outcomes. For viral systems, these stochastic effects become increasingly relevant at low multiplicity of infection (MOI) [36, 46]. However, even at high MOI, a range of cell-to-cell productivity spanning multiple orders of magnitude is often observed [46, 47]. Wild-type viral stochastic modeling is an active area of development, and models have been built for HIV [48], influenza [46], VSV [47], poliovirus [49], and others.

That said, these stochastic approaches have not been widely applied to recombinant systems. For linear systems and systems operating near the thermodynamic limit at higher numbers of substrates, deterministic and stochastic approaches should give similar results [50]. For some recombinant systems, such as monoclonal stable cell lines with multiple genomic copies, these assumptions likely hold, and deterministic approaches are sufficient. However, for recombinant systems operating with a lower or variable number of reactants, such as attenuated virus production processes, these assumptions may not be valid and stochastic elements can be considered.

3 Reactor-scale Models

3.1 Model Constituents

A mechanistic model of a viral bioreactor at bioreactor length and time scales needs to consider four aspects,

1. Bioreactor Configuration: The reactor design and operating conditions are vital in writing the governing conservation and balance equations describing the bioreactor.
2. Substrates and metabolites: A description of how key substrates and metabolites are transported into and out of the bioreactor along with their production and/or consumption by cells.

3. Viral Kinetics: A suitable model describing the kinetics of the viral infection and viral particle production process is needed to specify the kinetics terms in the model.
4. Biomass: A description of how the biomass evolves within the system.

While this review focuses primarily on reactor-scale viral kinetics and biomass descriptions, the other reactor model constituents will also be briefly considered.

3.2 Bioreactor Configuration

A variety of different bioreactor configurations for viral particle production have been explored in the literature [16, 51, 52]. The bioreactor configuration can have a significant impact on various aspects of the process such as its dynamics (e.g., undesirable oscillatory behaviour in viral titers can be eliminated by employing a tubular plug-flow reactor (PFR) instead of a continuously stirred tank reactor (CSTR) [53]), control, and optimization [16, 54]. While computational fluid dynamics (CFD) models can be constructed for bioreactor configurations to explore and identify an optimal design for a given process and viral system, commercial availability and practical limitations such as avoiding excessive shear stress and the need to get enough oxygen to the cells limit the choice of bioreactor configurations. Also, experimental validation of CFD models for some commercial bioreactor configurations are not available, so the predictive accuracy of these models for those configurations is unknown [55–58].

Given a choice of a bioreactor configuration, the corresponding macroscopic model equations can be derived by considering mass, species, and energy balances across the bioreactor, drawing upon concepts from an extensive chemical engineering literature (e.g., see [59–61] and citations therein). The model equations for CSTRs and batch bioreactors tend to be comparatively more straightforward (often expressible as ODEs and/or differential algebraic equations) than other bioreactor configurations (typically partial differential equations, PDEs) with terms containing spatial derivatives). The commonly employed assumption of perfect mixing in CSTR/batch reactors eliminate the need for the model to capture spatial variations in key variables. In subsequent sections, only CSTR/batch reactor models will be considered to simplify the presentation. The development of models for other bioreactor configurations is much more computationally expensive and in many cases remain an area of research [62, 63].

3.3 Substrates and Metabolites

The transport and consumption/production of key substrates (e.g., glucose, glutamate, and oxygen) and inhibitory metabolites (e.g., lactate and ammonium) can be captured by including suitable transport equations based on the bioreactor configuration (e.g., see [64–67]). Substrate- and metabolite-dependent effects on various terms such as the growth and death rates of cells can be correspondingly implemented in the model [68]. The bioreactor model can be simplified by omitting the model equations related to substrates and metabolites when these variables are kept constant as part of the reactor’s regulatory control policy and/or when the concentrations of specific substrates/metabolites of interest do not impact the process [69, 70].

3.4 Viral Kinetics and Biomass

For many viral systems, especially systems of infectious viral particles, the relationship between the virus particles and the biomass is closely coupled and are often considered together. Prior to formulating the model, it is helpful to consider a flow diagram to understand how the system dynamics impact the various components. As a first case, consider a simplified batch bioreactor with three species of interest: target cells (T), infected cells (I), and virus particles (V). The following assumptions are employed: Target cells grow exponentially with a rate constant μ , target cells are infected by attachment of free viral particles with a rate constant k_1 , target cells die with a rate constant k_2 , infected cells undergo apoptosis with a rate constant k_3 , virus particles are released upon apoptosis of infected cells with a proportionality constant k_4 , and free virus particles degrade with a rate constant k_5 . It is often helpful to construct a flowchart describing the processes of the system.

Figure 3 corresponds to one of the simplest models for viral particle production in a batch bioreactor,

$$\begin{aligned}\frac{dT}{dt} &= \mu T - k_1 TV - k_2 T, \\ \frac{dI}{dt} &= k_1 TV - k_3 I, \\ \frac{dV}{dt} &= -k_1 TV + k_4 I - k_5 V.\end{aligned}\tag{1}$$

This TIV model (and its variants, e.g., with additional terms to account for flow into and out of a bioreactor in a continuous CSTR or modifying various terms within (1) to more accurately reflect actual processes) have been used to model the production of viral particles of various viruses, e.g., Influenza [69, 71, 72], polio [73, 74], and dengue [75, 76]. As previously mentioned in the introduction, it is helpful to note the parallels between the TIV model and both patient viral infection dynamical models (e.g., see [77–79] and citations therein) and compartment models in epidemiology (see [80] and citations therein). These related fields have a rich literature which can serve as a source for formulating models and extensions. For recombinant systems where the viral particle does not infect cells in the bioreactor, the reactor-scale model would be much more closely aligned with well-established bioreactor models for recombinant protein production (e.g., see [81, 82]).

Multiple avenues for model extension are available. In some cases, it might be necessary to account for additional viral or cell species. For example, some viruses are known to produce defective interfering particles (DIPs) during replication which can impact system dynamics [71, 83]. Frensing *et al.* [71] extended the TIV model by including 3 additional equations to track DIPs, cells infected with DIPs and cells co-infected with DIPs and standard virus particles (STVs), and the proposed model was successfully able to qualitatively match experimental bioreactor results (see Figure 4 for exemplar simulations). To integrate deeper insights of the cell population into the model, the equations for one or more species of interest can be reformulated as a population balance model (PBM) with suitable intrinsic variables capturing the dimensions in which the population varies [84–86]. Table 3 summarizes exemplar intrinsic variables considered in cell population balance models with a focus on viral particle production.

4 Multiscale Models

Viral systems are inherently multiscale; infection and recombinant viral production are the result of a dynamic relationship between different time and length scales. Coupling the cellular- and reactor-scale dynamics can improve model accuracy and predictability for viral systems. This coupling often comes with increased model complexity and computational requirements, which can be mitigated via strategic application of simplifying assumptions and/or referral to the literature on the modeling and simulation of multiscale systems [87, 88].

The literature is sparse regarding multiscale modeling of recombinant viral systems. However, as with cellular- and reactor-scale models, analogous multiscale wild-type viral models can be leveraged for recombinant multiscale modeling [89]. These wild-type models are typically motivated by mapping the spread and treatment of a virus within a population, tissue, or cellular system, but many of the high-level mathematical approaches and considerations governing these systems are directly relevant to recombinant application [89]. Additionally, there are relevant multiscale publications on non-viral recombinant cellular systems (e.g., monoclonal antibodies), which are summarized by Kyriakopoulos *et al.* [90]. Note that multiscale models in which cellular-scale dynamics are paired with reactor-scale dynamics are often referred to as “structured” models in the literature [91].

One approach to incorporating multiscale dynamics is to couple the cellular-scale production of virus or VLP with the infectivity state of the cell population. Information is often transferred unidirectionally from the reactor-scale to the cellular-scale, such that the intracellular dynamics are affected by the infection state of the cell. Haseltine *et al.* [92] demonstrated this approach for a general viral infection system using a series of integro-partial differential equations. The group used simplifying assumptions to decouple the system [93], an approach that was also successfully employed to model Influenza A infection and antiviral efficacy [94]. Dürr *et al.* [95] extended this Influenza A infection model by using approximate moment methods to solve a population balance system, which was used to predict productivity effects due to heterogenous gene overexpression and expedited the screening of suitable cell line candidates [96]. Hu & Bentley [31] instead used a stochastic method to predict the infection pattern of a baculovirus insect system producing VLPs. Protein synthesis and VLP formation within individual cells was then tied to the time since infection and the number of infecting baculoviruses.

An alternative way to incorporate multiscale dynamics is to couple extracellular process variables to cellular-scale dynamics, which can prove useful for recombinant systems that do not contain live infection dynamics. For example, Ho *et al.* [97] linked the cellular-scale production of a monoclonal antibody to the reactor-scale glucose consumption [98] and Jedrzejewski *et al.* [99] used Monod kinetics to link extracellular metabolite concentrations to a cellular-scale glycosylation model [100]. These approaches linking cellular-scale dynamics to process variables have not been widely extended to segregated cell population models, where, for example, the infection status of individual cells is tracked. This simplification enables the model equations to remain a system of ODEs, greatly simplifying the solution approach. Future applications can extend these approaches to include the cellular-scale effects from other industry-relevant process variables such as dissolved oxygen and pH.

5 Parameter Estimation

A variety of parameter estimation techniques have been employed in the biological modeling literature to fit model parameters to experimental data. Methods include linear and nonlinear least squares [101], heuristic search algorithms [102, 103], and Kalman filtering [104], among others. For models of viral systems consisting of algebraic or differential equations in which the available data is limited and noisy, Bayesian techniques strike a balance between complexity and usefulness [105]. Since Bayesian estimation techniques allow inference of the entire probability distributions of the estimated parameters, they are also able to quantify the uncertainty in the parameter estimates. Bayes theorem describes the *a posteriori* distribution $P(\theta|\mathbf{Y})$ as a function of the experimental data \mathbf{Y} and the *a priori* distribution $P(\theta)$ of the model parameters θ ,

$$P(\theta|\mathbf{Y}) = \frac{P(\mathbf{Y}|\theta)P(\theta)}{P(\mathbf{Y})}. \quad (2)$$

Two parameter estimation approaches rooted in Bayes theorem are maximum likelihood (ML) and maximum a posteriori (MAP) estimation [105]. ML estimation assumes no prior knowledge is available other than potentially bounds on the model parameters, and $P(\theta)$ is assumed constant over the allowed parameters. Assuming zero-mean normally distributed noise and using a logarithmic transformation, the ML estimator can be written as a function of the vector of

measurements \mathbf{Y} and model outputs $f(\mathbf{X}, \boldsymbol{\theta})$ [105] by

$$\min_{\boldsymbol{\theta}} (\mathbf{Y} - f(\mathbf{X}, \boldsymbol{\theta}))^\top \mathbf{V}_\epsilon^{-1} (\mathbf{Y} - f(\mathbf{X}, \boldsymbol{\theta})) \quad (3)$$

where \mathbf{X} is the vector of state variables and \mathbf{V}_ϵ is the measurement error covariance matrix. ML estimation finds the parameters that have the highest likelihood of fitting the data. The MAP estimator extends the ML estimator by incorporating prior knowledge about the model parameters. This prior knowledge can be leveraged from literature results or previous experiments. Assuming zero-mean normally distributed noise and normally distributed priors with means $\boldsymbol{\mu}$ and variances \mathbf{V}_μ , the maximum *a posteriori* estimator is [105]

$$\min_{\boldsymbol{\theta}} (\mathbf{Y} - f(\mathbf{X}, \boldsymbol{\theta}))^\top \mathbf{V}_\epsilon^{-1} (\mathbf{Y} - f(\mathbf{X}, \boldsymbol{\theta})) + (\boldsymbol{\theta} - \boldsymbol{\mu})^\top \mathbf{V}_\mu^{-1} (\boldsymbol{\theta} - \boldsymbol{\mu}). \quad (4)$$

6 Conclusions

Demand is surging for products manufactured in viral systems. Nevertheless, the yields of even the most state-of-the-art recombinant viral systems often fall short of market needs. Improvements to recombinant viral processes are urgently needed to meet this demand and ensure the consistent manufacture of high-quality viral products. Dynamical modeling is one way to realize high-impact process gains; understanding the cellular- and reactor-scale dynamics can increase specific productivity, improve control of critical quality attributes (CQAs), and decrease the amount of time required for process development by encouraging targeted experimentation. modeling can also inform other methods of upstream process enhancement such as media development and process intensification, leading to even greater gains.

Many of the modeling methodologies summarized in this review were first applied to wild-type viral systems. Extending these approaches to recombinant systems is not trivial, and often requires experimentation for model validation. That said, advances in measurement technologies and synthetic biology will continue to improve the informativeness of experiments, enabling even more comprehensive models. Additionally, as more products made in viral systems mature and scale into manufacturing systems, dynamical models can be created with manufacturing-specific applications.

Acknowledgments

Financial support is acknowledged from the U.S. Food and Drug Administration (FD007458) and the Agency for Science, Technology and Research (A*STAR), Singapore.

References

1. Warnock, J. N., Daigre, C. & Al-Rubeai, M. in *Viral Vectors for Gene Therapy* (eds Merten, O. & Al-Rubeai, M.) 1st ed., 1–25 (Humana Press, New York, 2011).
2. Plotkin, S. History of vaccination. *Proceedings of the National Academy of Sciences* **111**, 12283–12287 (Aug. 2014).
3. Ura, T., Okuda, K. & Shimada, M. Developments in viral vector-based vaccines. *Vaccines* **2**, 624–641 (July 2014).
4. Mohsen, M. O., Zha, L., Cabral-Miranda, G. & Bachmann, M. F. Major findings and recent advances in virus-like particle (VLP)-based vaccines. *Seminars in Immunology* **34**, 123–132 (Dec. 2017).
5. Frensing, T. Defective interfering viruses and their impact on vaccines and viral vectors. *Biotechnology Journal* **10**, 681–689 (May 2015).
6. Shah, K. H., Almaghrabi, B. & Bohlmann, H. Comparison of expression vectors for transient expression of recombinant proteins in plants. *Plant Molecular Biology Reporter* **31**, 1529–1538 (Dec. 2013).
7. Wurm, F. & Bernard, A. Large-scale transient expression in mammalian cells for recombinant protein production. *Current Opinion in Biotechnology* **10**, 156–159 (Apr. 1999).
8. Wen, A. M. & Steinmetz, N. F. Design of virus-based nanomaterials for medicine, biotechnology, and energy. *Chemical Society Reviews* **45**, 4074–4126 (2016).
9. Ma, Y., Nolte, R. J. & Cornelissen, J. J. Virus-based nanocarriers for drug delivery. *Advanced Drug Delivery Reviews* **64**, 811–825 (June 2012).
10. Singh, N. & Heldt, C. L. Challenges in downstream purification of gene therapy viral vectors. *Current Opinion in Chemical Engineering* **35**, 100780 (Mar. 2022).
11. Nguyen, T. N., Sha, S., Hong, M. S., Maloney, A. J., Barone, P. W., Neufeld, C., Wolfrum, J., Springs, S. L., Sinskey, A. J. & Braatz, R. D. Mechanistic model for production of recombinant adeno-associated virus via triple transfection of HEK293 cells. *Molecular Therapy - Methods & Clinical Development* **21**, 642–655 (June 2021).
12. Kiesslich, S. & Kamen, A. A. Vero cell upstream bioprocess development for the production of viral vectors and vaccines. *Biotechnology Advances* **44**, 107608 (Nov. 2020).
13. Genzel, Y. Designing cell lines for viral vaccine production: Where do we stand? *Biotechnology Journal* **10**, 728–740 (May 2015).
14. Li, C. & Samulski, R. J. Engineering adeno-associated virus vectors for gene therapy. *Nature Reviews Genetics* **21**, 255–272 (Apr. 2020).
15. Jordan, I., Horn, D., John, K. & Sandig, V. A genotype of Modified Vaccinia Ankara (MVA) that facilitates replication in suspension cultures in chemically defined medium. *Viruses* **5**, 321–339 (Jan. 2013).
16. Gallo-Ramírez, L. E., Nikolay, A., Genzel, Y. & Reichl, U. Bioreactor concepts for cell culture-based viral vaccine production. *Expert Review of Vaccines* **14**, 1181–1195 (Sept. 2015).
17. Wolf, M. W. & Reichl, U. Downstream processing of cell culture-derived virus particles. *Expert Review of Vaccines* **10**, 1451–1475 (Oct. 2011).
18. Lee, S. Y., Lee, D.-Y. & Kim, T. Y. Systems biotechnology for strain improvement. *Trends in Biotechnology* **23**, 349–358 (July 2005).
19. Bailey, J. Mathematical modeling and analysis in biochemical engineering: Past accomplishments and future opportunities. *Biotechnology Progress* **14**, 8–20 (Feb. 1998).
20. Udugama, I. A., Lopez, P. C., Gargalo, C. L., Li, X., Bayer, C. & Gernaey, K. V. Digital Twin in biomanufacturing: challenges and opportunities towards its implementation. *Systems Microbiology and Biomanufacturing* **1**, 257–274 (July 2021).
21. Hong, M. S., Severson, K. A., Jiang, M., Lu, A. E., Love, J. C. & Braatz, R. D. Challenges and opportunities in biopharmaceutical manufacturing control. *Computers & Chemical Engineering* **110**, 106–114 (Feb. 2018).
22. Narayanan, H., Luna, M. F., Stosch, M., Cruz Bournazou, M. N., Polotti, G., Morbidelli, M., Butté, A. & Sokolov, M. Bioprocessing in the digital age: The role of process models. *Biotechnology Journal* **15**, 1900172 (Jan. 2020).
23. Gernaey, K. V., Lantz, A. E., Tufvesson, P., Woodley, J. M. & Sin, G. Application of mechanistic models to fermentation and biocatalysis for next-generation processes. *Trends in Biotechnology* **28**, 346–354 (July 2010).

24. Gastine, S., Pang, J., Boshier, F. A., Carter, S. J., Lonsdale, D. O., Cortina-Borja, M., Hung, I. F., Breuer, J., Klopogge, F. & Standing, J. F. Systematic review and patient-Level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapies. *Clinical Pharmacology & Therapeutics* **110**, 321–333 (Aug. 2021).
25. Hill, A. L., Rosenbloom, D. I. S., Nowak, M. A. & Siliciano, R. F. Insight into treatment of HIV infection from viral dynamics models. *Immunological Reviews* **285**, 9–25 (Sept. 2018).
26. Hadjichrysanthou, C., Cauët, E., Lawrence, E., Vegvari, C., de Wolf, F. & Anderson, R. M. Understanding the within-host dynamics of influenza A virus: from theory to clinical implications. *Journal of The Royal Society Interface* **13**, 20160289 (June 2016).
27. Annas, S., Isbar Pratama, M., Rifandi, M., Sanusi, W. & Side, S. Stability analysis and numerical simulation of SEIR model for pandemic COVID-19 spread in Indonesia. *Chaos, Solitons & Fractals* **139**, 110072 (Oct. 2020).
28. Carcione, J. M., Santos, J. E., Bagaini, C. & Ba, J. A simulation of a COVID-19 epidemic based on a deterministic SEIR model. *Frontiers in Public Health* **8** (May 2020).
29. Dinh, A.-T., Theofanous, T. & Mitragotri, S. A model for intracellular trafficking of adenoviral vectors. *Biophysical Journal* **89**, 1574–1588 (Sept. 2005).
30. Laske, T., Bachmann, M., Dostert, M., Karlas, A., Wirth, D., Frensing, T., Meyer, T. F., Hauser, H. & Reichl, U. Model-based analysis of influenza A virus replication in genetically engineered cell lines elucidates the impact of host cell factors on key kinetic parameters of virus growth. *PLOS Computational Biology* **15** (ed Lloyd-Smith, J.) e1006944 (Apr. 2019).
31. Hu, Y.-C. & Bentley, W. E. A kinetic and statistical-thermodynamic model for baculovirus infection and virus-like particle assembly in suspended insect cells. *Chemical Engineering Science* **55**, 3991–4008 (Oct. 2000).
32. Roldão, A., Vieira, H. L., Charpilienne, A., Poncet, D., Roy, P., Carrondo, M. J., Alves, P. M. & Oliveira, R. Modeling rotavirus-like particles production in a baculovirus expression vector system: Infection kinetics, baculovirus DNA replication, mRNA synthesis and protein production. *Journal of Biotechnology* **128**, 875–894 (Mar. 2007).
33. Yin, J. & Redovich, J. Kinetic modeling of virus growth in cells. *Microbiology and Molecular Biology Reviews* **82**, 1–33 (June 2018).
34. Bressloff, P. C. *Stochastic Processes in Cell Biology* (Springer International Publishing, Cham, 2014).
35. Tsimring, L. S. Noise in biology. *Reports on Progress in Physics* **77**, 026601 (Feb. 2014).
36. Srivastava, R., You, L., Summers, J. & Yin, J. Stochastic vs. Deterministic modeling of intracellular viral kinetics. *Journal of Theoretical Biology* **218**, 309–321 (Oct. 2002).
37. Hagan, M. F. in *Advances in Chemical Physics: Volume 155* (eds Rice, S. A. & Dinner, A. R.) 1st ed., 1–68 (John Wiley & Sons, Inc., Hoboken, New Jersey, Apr. 2014).
38. Perlmutter, J. D. & Hagan, M. F. Mechanisms of virus assembly. *Annual Review of Physical Chemistry* **66**, 217–239 (Apr. 2015).
39. Heldt, F. S., Frensing, T. & Reichl, U. Modeling the intracellular dynamics of Influenza virus replication to understand the control of viral RNA synthesis. *Journal of Virology* **86**, 7806–7817 (Aug. 2012).
40. Zitzmann, C., Schmid, B., Ruggieri, A., Perelson, A. S., Binder, M., Bartenschlager, R. & Kaderali, L. A coupled mathematical model of the intracellular replication of Dengue virus and the host cell immune response to infection. *Frontiers in Microbiology* **11** (Apr. 2020).
41. Grebennikov, D., Kholodareva, E., Sazonov, I., Karsonova, A., Meyerhans, A. & Bocharov, G. Intracellular life cycle kinetics of SARS-CoV-2 predicted using mathematical modelling. *Viruses* **13**, 1735 (Aug. 2021).
42. Aunins, T. R., Marsh, K. A., Subramanya, G., Uprichard, S. L., Perelson, A. S. & Chatterjee, A. Intracellular Hepatitis C virus modeling predicts infection dynamics and viral protein mechanisms. *Journal of Virology* **92** (ed Ou, J.-H. J.) (June 2018).
43. Shcherbatova, O., Grebennikov, D., Sazonov, I., Meyerhans, A. & Bocharov, G. Modeling of the HIV-1 life cycle in productively infected cells to predict novel therapeutic targets. *Pathogens* **9**, 255 (Mar. 2020).
44. Lim, K.-i., Lang, T., Lam, V. & Yin, J. Model-based design of growth-attenuated viruses. *PLoS Computational Biology* **2** (ed Reichl, U.) e116 (Sept. 2006).
45. Binder, M., Sulaimanov, N., Clausnitzer, D., Schulze, M., Hüber, C. M., Lenz, S. M., Schlöder, J. P., Trippler, M., Bartenschlager, R., Lohmann, V. & Kaderali, L. Replication vesicles are load- and choke-points in the Hepatitis C virus lifecycle. *PLoS Pathogens* **9** (ed Wilke, C. O.) e1003561 (Aug. 2013).

46. Heldt, F. S., Kupke, S. Y., Dorl, S., Reichl, U. & Frensing, T. Single-cell analysis and stochastic modelling unveil large cell-to-cell variability in influenza A virus infection. *Nature Communications* **6**, 8938 (Dec. 2015).
47. Hensel, S. C., Rawlings, J. B. & Yin, J. Stochastic kinetic modeling of vesicular stomatitis virus intracellular growth. *Bulletin of Mathematical Biology* **71**, 1671–1692 (Oct. 2009).
48. Sazonov, I., Grebennikov, D., Meyerhans, A. & Bocharov, G. Markov chain-based stochastic modelling of HIV-1 life cycle in a CD4 T cell. *Mathematics* **9**, 2025 (Aug. 2021).
49. Schulte, M. B., Draghi, J. A., Plotkin, J. B. & Andino, R. Experimentally guided models reveal replication principles that shape the mutation distribution of RNA viruses. *eLife* **4** (Jan. 2015).
50. Hahl, S. K. & Kremling, A. A comparison of deterministic and stochastic modeling approaches for biochemical reaction systems: On fixed points, means, and modes. *Frontiers in Genetics* **7** (Aug. 2016).
51. Grein, T. A., Weidner, T. & Czermak, P. in *New Insights into Cell Culture Technology* (InTech, May 2017).
52. Gutiérrez-Granados, S., Gòdia, F. & Cervera, L. Continuous manufacturing of viral particles. *Current Opinion in Chemical Engineering* **22**, 107–114 (Dec. 2018).
53. Tapia, F., Wohlfarth, D., Sandig, V., Jordan, I., Genzel, Y. & Reichl, U. Continuous influenza virus production in a tubular bioreactor system provides stable titers and avoids the “von Magnus effect”. *PLOS ONE* **14** (ed Beato, M. S.) e0224317 (Nov. 2019).
54. Yamuna Rani, K. & Ramachandra Rao, V. S. Control of fermenters – a review. *Bioprocess Engineering* **21**, 77–88 (July 1999).
55. Karimi Alavijeh, M., Baker, I., Lee, Y. Y. & Gras, S. L. Digitally enabled approaches for the scale up of mammalian cell bioreactors. *Digital Chemical Engineering* **4**, 100040 (Sept. 2022).
56. Nadal-Rey, G., McClure, D. D., Kavanagh, J. M., Cassells, B., Cornelissen, S., Fletcher, D. F. & Gernaey, K. V. Computational fluid dynamics modelling of hydrodynamics, mixing and oxygen transfer in industrial bioreactors with Newtonian broths. *Biochemical Engineering Journal* **177**, 108265 (Jan. 2022).
57. Scully, J., Considine, L. B., Smith, M. T., McAlea, E., Jones, N., O’Connell, E., Madsen, E., Power, M., Mellors, P., Crowley, J., O’Leary, N., Carver, S. & Van Plew, D. Beyond heuristics: CFD-based novel multiparameter scale-up for geometrically disparate bioreactors demonstrated at industrial 2kL–10kL scales. *Biotechnology and Bioengineering* **117**, 1710–1723 (June 2020).
58. Löffelholz, C., Kaiser, S. C., Kraume, M., Eibl, R. & Eibl, D. in *Disposable Bioreactors II* (eds Eibl, D. & Eibl, R.) 1st ed., 1–44 (Springer Berlin Heidelberg, Heidelberg, 2013).
59. O’Levenspiel. *Chemical Reaction Engineering* 3rd ed. (John Wiley & Sons, New York, 1999).
60. G.F.Froment, K.B. Bischoff & DeWilde, J. *Chemical Reactor Analysis and Design* 3rd ed. (John Wiley & Sons, Inc., Hoboken, NJ, USA, 2010).
61. Fogler, S. H. *Elements of Chemical Reaction Engineering* 5th ed. (Prentice Hall, 2016).
62. Teng, X., Li, C., Yi, X. & Zhuang, Y. A novel scale-up strategy for cultivation of BHK-21 cells based on similar hydrodynamic environments in the bioreactors. *Bioresources and Bioprocessing* **8**, 74 (Dec. 2021).
63. Li, X.-R., Yang, Y.-K., Wang, R.-B., An, F.-L., Zhang, Y.-D., Nie, J.-Q., Ahamada, H., Liu, X.-X., Liu, C.-L., Deng, Y., Bai, Z.-H., Li, Y. & Liu, X.-R. A scale-down model of 4000-L cell culture process for inactivated foot-and-mouth disease vaccine production. *Vaccine* **37**, 6380–6389 (Oct. 2019).
64. Hong, M. S. & Braatz, R. D. Mechanistic modeling and parameter-adaptive nonlinear model predictive control of a microbioreactor. *Computers & Chemical Engineering* **147**, 107255 (Apr. 2021).
65. Craven, S., Whelan, J. & Glennon, B. Glucose concentration control of a fed-batch mammalian cell bioprocess using a nonlinear model predictive controller. *Journal of Process Control* **24**, 344–357 (Apr. 2014).
66. Craven, S., Shirsat, N., Whelan, J. & Glennon, B. Process model comparison and transferability across bioreactor scales and modes of operation for a mammalian cell bioprocess. *Biotechnology Progress* **29**, 186–196 (Jan. 2013).
67. Brotherton, J. & Chau, P. Modeling of axial-flow hollow fiber cell culture bioreactors. *Biotechnology Progress* **12**, 575–590 (Oct. 1996).
68. Pörtner, R. & Schäfer, T. Modelling hybridoma cell growth and metabolism — a comparison of selected models and data. *Journal of Biotechnology* **49**, 119–135 (Aug. 1996).
69. Möhler, L., Flockerzi, D., Sann, H. & Reichl, U. Mathematical model of influenza A virus production in large-scale microcarrier culture. *Biotechnology and Bioengineering* **90**, 46–58 (Apr. 2005).

70. Genzel, Y., Behrendt, I., König, S., Sann, H. & Reichl, U. Metabolism of MDCK cells during cell growth and influenza virus production in large-scale microcarrier culture. *Vaccine* **22**, 2202–2208 (June 2004).
71. Frensing, T., Heldt, F. S., Pflugmacher, A., Behrendt, I., Jordan, I., Flockerzi, D., Genzel, Y. & Reichl, U. Continuous Influenza virus production in cell culture shows a periodic accumulation of defective interfering particles. *PLoS ONE* **8** (ed Pöhlmann, S.) e72288 (Sept. 2013).
72. Schulze-Horsel, J., Schulze, M., Agalaridis, G., Genzel, Y. & Reichl, U. Infection dynamics and virus-induced apoptosis in cell culture-based influenza vaccine production—Flow cytometry and mathematical modeling. *Vaccine* **27**, 2712–2722 (May 2009).
73. Jiang, Y., van der Welle, J. E., Rubingh, O., van Eikenhorst, G., Bakker, W. A. & Thomassen, Y. E. Kinetic model for adherent Vero cell growth and poliovirus production in batch bioreactors. *Process Biochemistry* **81**, 156–164 (June 2019).
74. Ursache, R. V., Thomassen, Y. E., van Eikenhorst, G., Verheijen, P. J. T. & Bakker, W. A. M. Mathematical model of adherent Vero cell growth and poliovirus production in animal component free medium. *Bioprocess and Biosystems Engineering* **38**, 543–555 (Mar. 2015).
75. Abbate, T., Dewasme, L. & Vande Wouwer, A. Variable selection and parameter estimation of viral amplification in vero cell cultures dedicated to the production of a dengue vaccine. *Biotechnology Progress* **35**, e2687 (Jan. 2019).
76. Abbate, T., Dewasme, L. & Wouwer, A. V. Dynamic macroscopic model of dengue viral amplification in vero cell cultures. *IFAC-PapersOnLine* **49**, 159–164 (2016).
77. Hernandez-Vargas, E. A. & Velasco-Hernandez, J. X. In-host mathematical modelling of COVID-19 in humans. *Annual Reviews in Control* **50**, 448–456 (2020).
78. Perelson, A. S. & Ribeiro, R. M. Modeling the within-host dynamics of HIV infection. *BMC Biology* **11**, 96 (Dec. 2013).
79. Saenz, R. A., Quinlivan, M., Elton, D., MacRae, S., Blunden, A. S., Mumford, J. A., Daly, J. M., Digard, P., Cullinane, A., Grenfell, B. T., McCauley, J. W., Wood, J. L. N. & Gog, J. R. Dynamics of Influenza virus infection and pathology. *Journal of Virology* **84**, 3974–3983 (Apr. 2010).
80. *Mathematical Epidemiology* 1st ed. (eds Brauer, F., van den Driessche, P. & Wu, J.) (Springer Berlin Heidelberg, Berlin, Heidelberg, 2008).
81. Liu, S. *Bioprocess Engineering* 3rd ed. (Elsevier, Amsterdam, 2020).
82. McDuffie, N. *Bioreactor Design Fundamentals* (Butterworth-Heinemann, Boston, 1991).
83. Shirogane, Y., Rousseau, E., Voznica, J., Xiao, Y., Su, W., Catching, A., Whitfield, Z. J., Rouzine, I. M., Bianco, S. & Andino, R. Experimental and mathematical insights on the interactions between poliovirus and a defective interfering genome. *PLOS Pathogens* **17** (ed Semler, B. L.) e1009277 (Sept. 2021).
84. Inguva, P. & Braatz, R. D. Efficient numerical schemes for multidimensional population balance models. *arXiv* (June 2022).
85. Inguva, P. K., Schickel, K. C. & Braatz, R. D. Efficient numerical schemes for population balance models. *Computers & Chemical Engineering* **162**, 107808 (June 2022).
86. Villadsen, J., Nielsen, J. & Lidén, G. *Bioreaction Engineering Principles* 3rd ed. (Springer US, Boston, MA, 2011).
87. Raimondeau, S. & Vlachos, D. Recent developments on multiscale, hierarchical modeling of chemical reactors. *Chemical Engineering Journal* **90**, 3–23 (Nov. 2002).
88. Ingram, G., Cameron, I. & Hantos, K. Classification and analysis of integrating frameworks in multiscale modelling. *Chemical Engineering Science* **59**, 2171–2187 (June 2004).
89. Garira, W. A complete categorization of multiscale models of infectious disease systems. *Journal of Biological Dynamics* **11**, 378–435 (Jan. 2017).
90. Kyriakopoulos, S., Ang, K. S., Lakshmanan, M., Huang, Z., Yoon, S., Gunawan, R. & Lee, D.-Y. Kinetic modeling of mammalian cell culture bioprocessing: The quest to advance biomanufacturing. *Biotechnology Journal* **13**, 1700229 (Mar. 2018).
91. Bailey, J. & Ollis, D. *Biochemical Engineering Fundamentals* (McGraw-Hill, 1986).
92. Haseltine, E. L., Rawlings, J. B. & Yin, J. Dynamics of viral infections: incorporating both the intracellular and extracellular levels. *Computers & Chemical Engineering* **29**, 675–686 (Feb. 2005).
93. Haseltine, E. L., Yin, J. & Rawlings, J. B. Implications of decoupling the intracellular and extracellular levels in multi-level models of virus growth. *Biotechnology and Bioengineering* **101**, 811–820 (Nov. 2008).

94. Heldt, F. S., Frensing, T., Pflugmacher, A., Gröpler, R., Peschel, B. & Reichl, U. Multiscale modeling of Influenza A virus infection supports the development of direct-acting antivirals. *PLoS Computational Biology* **9** (ed Koelle, K.) e1003372 (Nov. 2013).
95. Dürr, R., Müller, T., Duvigneau, S. & Kienle, A. An efficient approximate moment method for multi-dimensional population balance models – Application to virus replication in multi-cellular systems. *Chemical Engineering Science* **160**, 321–334 (Mar. 2017).
96. Duvigneau, S., Dürr, R., Laske, T., Bachmann, M., Dostert, M. & Kienle, A. Model-based approach for predicting the impact of genetic modifications on product yield in biopharmaceutical manufacturing—Application to influenza vaccine production. *PLOS Computational Biology* **16** (ed Alber, M.) e1007810 (June 2020).
97. Ho, Y., Varley, J. & Mantalaris, A. Development and analysis of a mathematical model for antibody-producing GS-NS0 cells under normal and hyperosmotic culture conditions. *Biotechnology Progress* **22**, 1560–1569 (Dec. 2006).
98. Bibila, T. & Flickinger, M. C. A structured model for monoclonal antibody synthesis in exponentially growing and stationary phase hybridoma cells. *Biotechnology and Bioengineering* **37**, 210–226 (Feb. 1991).
99. Jedrzejewski, P., del Val, I., Constantinou, A., Dell, A., Haslam, S., Polizzi, K. & Kontoravdi, C. Towards controlling the glycoform: A model framework linking extracellular metabolites to antibody glycosylation. *International Journal of Molecular Sciences* **15**, 4492–4522 (Mar. 2014).
100. Jimenez del Val, I., Nagy, J. M. & Kontoravdi, C. A dynamic mathematical model for monoclonal antibody N-linked glycosylation and nucleotide sugar donor transport within a maturing Golgi apparatus. *Biotechnology Progress* **27**, 1730–1743 (Nov. 2011).
101. Mendes, P. & Kell, D. Non-linear optimization of biochemical pathways: applications to metabolic engineering and parameter estimation. *Bioinformatics* **14**, 869–883 (Nov. 1998).
102. Srinivas, M. & Patnaik, L. Genetic algorithms: a survey. *Computer* **27**, 17–26 (June 1994).
103. Calvez, B. & Hutzler, G. in *Multi-Agent-Based Simulation VI. MABS 2005* (eds Sichman, J. & Antunes, L.) 1st ed., 41–57 (Springer Berlin Heidelberg, 2006).
104. Lillacci, G. & Khammash, M. Parameter estimation and model selection in computational biology. *PLoS Computational Biology* **6** (ed Asthagiri, A. R.) e1000696 (Mar. 2010).
105. Beck, J. V. & Arnold, K. J. *Parameter Estimation in Engineering and Science* (Wiley, New York, NY, 1977).
106. Dee, K. U. & Shuler, M. L. A mathematical model of the trafficking of acid-dependent enveloped viruses: Application to the binding, uptake, and nuclear accumulation of baculovirus. *Biotechnology and Bioengineering* **54**, 468–490 (June 1997).
107. Nunes-Correia, I., Ramalho-Santos, J., Nir, S. & Pedroso de Lima, M. C. Interactions of Influenza virus with cultured cells: Detailed kinetic modeling of binding and endocytosis. *Biochemistry* **38**, 1095–1101 (Jan. 1999).
108. Schmidt, K. & Sawodny, O. *Efficient simulation of semilinear populations models for age-structured bio reactors* in *2017 IEEE Conference on Control Technology and Applications (CCTA)* (IEEE, Aug. 2017), 1716–1721.
109. Kurtz, M. J., Zhu, G.-Y., Zamamiri, A., Henson, M. A. & Hjortsø, M. A. Control of oscillating microbial cultures described by population balance models. *Industrial & Engineering Chemistry Research* **37**, 4059–4070 (Oct. 1998).
110. Quedeville, V., Ouazaite, H., Polizzi, B., Fox, R., Villedieu, P., Fede, P., Létisse, F. & Morchain, J. A two-dimensional population balance model for cell growth including multiple uptake systems. *Chemical Engineering Research and Design* **132**, 966–981 (Apr. 2018).
111. Abia, L., Angulo, O., López-Marcos, J. & López-Marcos, M. Numerical schemes for a size-structured cell population model with equal fission. *Mathematical and Computer Modelling* **50**, 653–664 (Sept. 2009).
112. Mantzaris, N. V., Liou, J.-J., Daoutidis, P. & Sreenc, F. Numerical solution of a mass structured cell population balance model in an environment of changing substrate concentration. *Journal of Biotechnology* **71**, 157–174 (May 1999).
113. Fischer, D. S., Fiedler, A. K., Kernfeld, E. M., Genga, R. M. J., Bastidas-Ponce, A., Bakhti, M., Lickert, H., Hasenauer, J., Maehr, R. & Theis, F. J. Inferring population dynamics from single-cell RNA-sequencing time series data. *Nature Biotechnology* **37**, 461–468 (Apr. 2019).

114. Fadda, S., Cincotti, A. & Cao, G. A novel population balance model to investigate the kinetics of in vitro cell proliferation: Part I. model development. *Biotechnology and Bioengineering* **109**, 772–781 (Mar. 2012).
115. Liu, Y.-H., Bi, J.-X., Zeng, A.-P. & Yuan, J.-Q. A population balance model describing the cell cycle dynamics of myeloma cell cultivation. *Biotechnology Progress* **23**, 1198–1209 (Aug. 2007).
116. Müller, T., Dürr, R., Isken, B., Schulze-Horsel, J., Reichl, U. & Kienle, A. Distributed modeling of human influenza a virus-host cell interactions during vaccine production. *Biotechnology and Bioengineering* **110**, 2252–2266 (Aug. 2013).
117. Dürr, R., Müller, T., Isken, B., Schulze-Horsel, J., Reichl, U. & Kienle, A. Distributed modeling and parameter estimation of Influenza virus replication during vaccine production. *IFAC Proceedings Volumes* **45**, 320–325 (2012).
118. Müller, T., Schulze-Horsel, J., Sidorenko, Y., Reichl, U. & Kienle, A. *Population balance modeling of influenza virus replication in MDCK cells during vaccine production* in *18th European Symposium on Computer Aided Process Engineering* (eds Braunschweig, B. & Joulia, X.) (Elsevier Science, Lyon, France, 2008), 133–138.
119. Nguyen, T. N. *tamntnguyen/AAV-Triple-Transfection-Mechanistic-Model* 2021. <https://github.com/tamntnguyen/AAV-Triple-Transfection-Mechanistic-Model>.
120. Müller, T. *Population balance modeling of influenza A virus replication in MDCK cells during vaccine production* PhD thesis (Otto-von-Guericke University Magdeburg, 2015).

List of Tables

1	Mathematical approaches used in cellular-scale viral models. Many of the process steps summarized in Figure 1 have been described using multiple mathematical approaches.	14
2	Variables used in Table 1 to describe cellular-scale modeling mathematical approaches.	14
3	Exemplar intrinsic variables considered in PBMs for biotechnology. Where possible, references to the literature considering viral systems are provided.	15

Table 1: Mathematical approaches used in cellular-scale viral models. Many of the process steps summarized in Figure 1 have been described using multiple mathematical approaches.

Mathematical Approach	Equation Structure	Step	References
Power Law	$v_o = k \prod_i^N [S_i]^{\alpha_i}$	Plasmid Uptake (1A)	[11]
		Viral Uptake (1B)	[40, 41, 44]
		Unpacking (2)	[39]
		Migration to Nucleus (3)	[39, 106]
		Replication (4)	[32, 42]
		Transcription (5)	[32]
		Translation (6)	[39, 41]
		Assembly (7)	[11, 42, 43]
		Release (8)	[11, 41]
Power Law with Limiting or Regulating Protein	$\frac{d[C_i]}{dt} = k_b[P_i][S_i]$ $\frac{d[S_{i+1}]}{dt} = k[C_i]$	Viral Uptake (1B)	[32, 39, 106, 107]
		Replication (4)	[39, 40, 44]
		Transcription (5)	[40, 44]
		Translation (6)	[40, 42, 44, 45]
Power Law With Time Delay	$v_o = k[S_i](t - \delta_t)$	Migration to Nucleus (3)	[32]
		Translation (6)	[31]
Michaelis-Menton	$v_o = \frac{v_{max}[S_i]}{[S_i] + K_M}$	Transcription (5)	[41]
		Translation (6)	[32]
		Assembly (7)	[39–41]
Thermodynamics	$[n] = \prod_{i=2}^n K_i[1]^n$	Assembly (7)	[31]

Table 2: Variables used in Table 1 to describe cellular-scale modeling mathematical approaches.

Variable	Description
C_i	Protein complex i
k	Rate constant
K_i	Association constant
K_m	Concentration of substrate needed to achieve half the maximal reaction rate
n	Number of subunits in VLP
N	Number of reacting species
P_i	Binding protein i
S_i	Reactant i
v_{max}	Maximum achievable reaction rate
v_o	Rate of reaction
α_i	Order of reactant i

Table 3: Exemplar intrinsic variables considered in PBMs for biotechnology. Where possible, references to the literature considering viral systems are provided.

Intrinsic variable	Description	Reference
Cell age/ Post-infection cell age	Enables age-based effects e.g., cell death and reproduction to be captured	[92, 93, 108, 109]
Cell mass/volume/size	These properties can be measured and used to capture similar effects as cell age	[110–112]
Intracellular DNA/RNA content	Provide deeper insights into the cell state	[95, 113–115]
Fluorescence	Provides information on the extent/progress of infection in the cell population. Data can be obtained from flow cytometry	[116–118]

List of Figures

- 1 Typical steps included in cellular-scale models of recombinant viral systems. Gene delivery to a host cell via (A) plasmid transfection and (B) recombinant viral infection. (C) Production of a viral vector via a stable cell line. 16
- 2 Dynamical cellular-scale model outputs for a recombinant AAV production process. In this study, Nguyen *et al.* [11] created a model mapping the generation of recombinant AAVs via transient transfection. The model was fit to experimental results and used to elucidate the mechanisms driving the low proportion of full capsids produced by the system. These plots were regenerated using software available at github [119]. 17
- 3 Flowchart for a simplified TIV system adapted from [69]; see [120] for additional examples of flow charts for more complex systems. 17
- 4 Exemplar reactor-scale simulations performed using the TIV (left) and extended model (right) in a CSTR from [71]. Frensing *et al.* [71] observed oscillatory behaviour during experimental runs which was explained by the presence of DIPs. This effect was captured in the extended model which introduced additional species to track DIPs and cells either infected with DIPs or co-infected cells. 18




Figure 1: Typical steps included in cellular-scale models of recombinant viral systems. Gene delivery to a host cell via (A) plasmid transfection and (B) recombinant viral infection. (C) Production of a viral vector via a stable cell line.




Figure 2: Dynamical cellular-scale model outputs for a recombinant AAV production process. In this study, Nguyen *et al.* [11] created a model mapping the generation of recombinant AAVs via transient transfection. The model was fit to experimental results and used to elucidate the mechanisms driving the low proportion of full capsids produced by the system. These plots were regenerated using software available at github [119].




Figure 3: Flowchart for a simplified TIV system adapted from [69]; see [120] for additional examples of flow charts for more complex systems.




Figure 4: Exemplar reactor-scale simulations performed using the TIV (left) and extended model (right) in a CSTR from [71]. Frensing *et al.* [71] observed oscillatory behaviour during experimental runs which was explained by the presence of DIPs. This effect was captured in the extended model which introduced additional species to track DIPs and cells either infected with DIPs or co-infected cells.